Erdosteine: antitussive and anti-inflammatory effects

Area of Science:

• Respiratory Medicine
• Pharmacology
• Oxidative Stress Research

Background:

• Erdosteine is a multifactorial drug used in COPD for its rheologic and anti-adhesive properties.
• Its active metabolite (Met 1) exhibits antioxidant effects, particularly during the respiratory burst of human neutrophils.
• While mucolytics are not consistently effective for cough, erdosteine has shown substantial antitussive effects.

Purpose of the Study:

• To investigate the antitussive, anti-inflammatory, and antioxidant properties of erdosteine in COPD.
• To explore erdosteine's effect on airway responsiveness to salbutamol in COPD patients.
• To elucidate the mechanisms underlying erdosteine's multifactorial actions in COPD.

Main Methods:

• Controlled studies, including double-blind placebo and N-acetylcysteine (NAC) comparisons, were conducted.
• Assessed antioxidant properties, including reactive oxygen species (ROS) scavenging and lipoperoxidation inhibition (8-isoprostane).
• Evaluated short-term airway response to salbutamol in COPD subjects unresponsive to beta(2)-adrenergics.

Main Results:

• Erdosteine demonstrated significant antioxidant and anti-inflammatory effects, inhibiting inflammatory mediators and cytokines.
• Erdosteine consistently restored short-term airway reversibility to salbutamol in COPD patients.
• Its ROS scavenging and lipoperoxidation inhibiting activities were comparable to NAC, but its effect on airway reversibility was unique.

Conclusions:

• Erdosteine's multifactorial properties stem from its antioxidant and anti-inflammatory actions.
• It may improve mucociliary clearance and reduce chemokines, contributing to antitussive effects.
• Erdosteine's potential to sensitize beta-adrenoceptors suggests a novel therapeutic role in COPD.